Skip to content

Author

J. Mahlangu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Future management of hemophilia a with non-biologic hemostatic agents: a call for precision coagulation.

INTRODUCTION The therapeutic landscape of hemophilia A has expanded beyond factor replacement with the emergence of non-biologic pharmacological strategies that modulate endogenous hemostatic pathways. These innovations challenge traditional treatment paradigms and create opportunities for more individualized approache...

J. Mahlangu · 0 citations
Review Sep 2026

An evaluation of denecimig for bleeding prophylaxis in hemophilia A.

INTRODUCTION Despite advances in factor VIII (FVIII) replacement and emicizumab prophylaxis, people with hemophilia A may experience breakthrough bleeding, progressive joint disease, treatment burden, and inhibitor-related limitations. Denecimig (Mim8) is a fully human, next-generation FVIIIa-mimetic bispecific antibod...

J. Mahlangu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.